i'm going to speak, my name is eric turner. sorry, i didn't introduce myself. i am a psychiatrist by training and former fda reviewer. may i speak from perspective as a clinician and also as former fda reviewer, as consumer of the information as well as participant in production of the information. so first of all, and one theme i want to touch on is not just qualitative types of thing disclosed but the manner in which it is disclosed and get at the idea of transparency versus translus ensee. you can think about more transparency, and that's a continuum, not either or thing. one thing i want to talk about is drug approval packages where i have done most of my research work with. i was told back when i was an fda reviewer when the fruits of my labor were complete and the drug were approved, then my review would be up on the internet for the world to see and that was kind of sobering. i knew that i was charged with an important job and that if i messed up, it would be there for the world to see. so one of my first reviews i worked on was, and i think i can say it